{
  "authors": [
    {
      "author": "ZoÃ« Blake"
    },
    {
      "author": "Douglas K Marks"
    },
    {
      "author": "Robyn D Gartrell"
    },
    {
      "author": "Thomas Hart"
    },
    {
      "author": "Patti Horton"
    },
    {
      "author": "Simon K Cheng"
    },
    {
      "author": "Bret Taback"
    },
    {
      "author": "Basil A Horst"
    },
    {
      "author": "Yvonne M Saenger"
    }
  ],
  "doi": "10.1186/s40425-018-0338-6",
  "publication_date": "2018-04-07",
  "id": "EN113404",
  "url": "https://pubmed.ncbi.nlm.nih.gov/29622046",
  "source": "Journal for immunotherapy of cancer",
  "source_url": "",
  "licence": "CC BY-NC",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We describe the case of a patient with diffusely metastatic melanoma, including brain metastases, who, despite being treated with stereotactic radiosurgery and dual CTLA-4/PD-1 blockade (ipilimumab/nivolumab), developed systemic disease progression and innumerable brain metastases. This patient achieved a complete CNS response and partial systemic response with standard whole brain radiation therapy (WBRT) combined with Talimogene laherparepvec (T-Vec) and pembrolizumab."
}